Last updated: September 24, 2026
Fosinopril sodium is an established, multisource ACE inhibitor with no meaningful remaining U.S. market exclusivity. Commercial opportunities center on low-cost tablet manufacturing, excipient substitution, fixed-dose combinations, alternative oral dosage forms, and supply-chain differentiation rather than basic active-ingredient patent protection. The strongest formulation strategy is a robust immediate-release tablet using widely available excipients, with separate opportunities in pediatric-compatible liquids, orally disintegrating tablets, and fosinopril/hydrochlorothiazide combinations.
What is the FDA status of fosinopril sodium?
Fosinopril sodium is an FDA-approved angiotensin-converting enzyme inhibitor marketed originally as Monopril by Bristol-Myers Squibb. FDA approved fosinopril sodium tablets in 1991 for hypertension and as adjunctive therapy in heart failure. The drug is administered orally and is converted in vivo to fosinoprilat, the active ACE-inhibiting compound. The labeling covers 10 mg, 20 mg, and 40 mg tablets, with dosing adjusted according to indication, renal function, diuretic use, and patient response (FDA, 2017).
| Attribute |
Fosinopril sodium |
| Active ingredient |
Fosinopril sodium |
| Therapeutic class |
ACE inhibitor |
| Active metabolite |
Fosinoprilat |
| Original brand |
Monopril |
| U.S. approval |
1991 |
| Dosage form |
Immediate-release oral tablet |
| Common strengths |
10 mg, 20 mg, 40 mg |
| Approved indications |
Hypertension; heart failure adjunct therapy |
| U.S. regulatory pathway |
ANDA generic competition |
| Biosimilar pathway |
Not applicable |
| Current reference-product exclusivity |
None identified |
| Current commercial position |
Generic, multisource product |
The product is a small-molecule drug, not a biologic. Biosimilar litigation, reference-product biologic exclusivity, and the Biologics Price Competition and Innovation Act pathway therefore do not apply.
When does fosinopril sodium lose exclusivity?
Fosinopril sodium lost meaningful U.S. exclusivity years ago. Its original compound and product-protection period expired before the current generic market developed, and the product is now available through multiple abbreviated new drug applications.
The relevant commercial conclusion is that a new manufacturer does not need to wait for an exclusivity event to enter the U.S. market. The principal requirements are ANDA approval, therapeutic equivalence, acceptable chemistry and manufacturing controls, and commercial supply economics.
What is the Orange Book status of fosinopril sodium?
The FDA Orange Book identifies approved fosinopril sodium products and their reference-product relationship. Current commercial listings are dominated by generic products rather than a protected branded product. The Orange Book does not create exclusivity; it records approval, therapeutic-equivalence evaluations, patents, and exclusivity information where applicable (FDA, n.d.-a).
A prospective entrant should assess:
- Whether the specific strength has an active reference-listed drug.
- Whether the target product requires an ANDA or another application type.
- Whether any listed method-of-use patent affects the proposed labeling.
- Whether the intended product is a tablet, combination product, or alternative dosage form.
- Whether the proposed product uses an excipient or manufacturing process requiring additional review.
How many patents cover fosinopril sodium?
The original fosinopril compound and associated product claims are historical rather than current barriers to routine generic entry. No active, commercially significant U.S. patent estate is generally associated with the standard immediate-release fosinopril sodium tablet.
The patent-risk profile is therefore low for the conventional product but can change for:
- New liquid formulations.
- Orally disintegrating tablets.
- Taste-masked systems.
- Sustained-release delivery.
- Fixed-dose combinations.
- Novel salt or polymorph forms.
- Manufacturing processes with unusually narrow claim scope.
- Specific patient populations or dosing regimens.
A formulation patent would need to claim a technically defined composition or performance result. A patent that merely substitutes one conventional filler for another would face a high obviousness risk unless it produces an unexpected stability, dissolution, compressibility, or bioavailability benefit.
Are Paragraph IV challenges relevant?
Paragraph IV litigation is unlikely to be a central issue for standard fosinopril sodium tablets because the basic product is long off patent and multiple generic products are already approved. A Paragraph IV certification could still arise against a newly listed patent covering a novel formulation, combination, or delivery system, but the ordinary 10 mg, 20 mg, and 40 mg immediate-release tablets do not present a typical active-patent challenge environment.
The most probable entry pathway for a new manufacturer is a standard ANDA based on bioequivalence to the reference product. A 180-day generic exclusivity event would matter only if a qualifying first applicant successfully challenged a listed patent or received another form of statutory exclusivity. That is not the prevailing commercial structure for conventional fosinopril sodium.
What excipients are used in fosinopril sodium tablets?
Fosinopril sodium tablets are generally formulated with conventional immediate-release excipients. Public labels for generic products identify combinations that can include lactose, microcrystalline cellulose, crospovidone or croscarmellose sodium, povidone, sodium stearyl fumarate, and colloidal silicon dioxide. The precise composition varies by manufacturer and strength (DailyMed, n.d.-a; DailyMed, n.d.-b).
| Excipient function |
Common candidates |
Strategic purpose |
| Diluent |
Lactose, microcrystalline cellulose |
Tablet mass and compressibility |
| Superdisintegrant |
Crospovidone, croscarmellose sodium |
Rapid tablet breakup |
| Binder |
Povidone |
Granule and tablet strength |
| Lubricant |
Sodium stearyl fumarate, magnesium stearate |
Ejection and tooling control |
| Glidant |
Colloidal silicon dioxide |
Powder flow |
| Film coating |
Hypromellose, polyethylene glycol, titanium dioxide, iron oxides |
Appearance, handling, identification |
Excipient selection should account for the active ingredient’s salt form, dose-to-tablet-mass ratio, moisture sensitivity, dissolution profile, and target manufacturing process. Direct compression can reduce process steps, but roller compaction or wet granulation may be preferable where powder flow and content uniformity are difficult to control.
Is lactose a suitable excipient?
Lactose is commercially attractive because it is inexpensive, widely available, and familiar to regulators. It can improve tablet mass and manufacturability when the active dose is relatively low. Its limitations include patient or market preferences involving lactose, possible compatibility considerations, and dependence on the selected manufacturing process.
A lactose-free product using microcrystalline cellulose, mannitol, dibasic calcium phosphate, or another diluent can support differentiated procurement and marketing. The substitution alone is unlikely to create durable patent value. Its commercial value is more likely to arise from a defined patient or market requirement.
What is the role of superdisintegrants?
Crospovidone and croscarmellose sodium can provide rapid disintegration in an immediate-release tablet. Their performance depends on particle size, grade, concentration, compression force, and lubricant exposure. Over-lubrication can slow wetting and dissolution, while excessive compression can reduce tablet porosity.
A formulation developer should optimize disintegration and dissolution against the reference product rather than treating excipient identity as the only critical variable. The key quality attributes are typically assay, content uniformity, degradation products, dissolution, hardness, friability, disintegration, and stability.
What formulation opportunities exist for fosinopril sodium?
Low-cost immediate-release tablets
The largest addressable opportunity remains a reliable generic tablet. A manufacturer can compete through:
- Lower excipient cost.
- Direct-compression processing.
- High-speed coating and packaging.
- Reduced tablet weight.
- Stable global sourcing.
- Strength-specific tooling.
- Multi-market documentation using a common core formula.
The product is suitable for contract manufacturing and private-label distribution because the dosage form is conventional and the drug does not require sterile processing or cold-chain logistics.
Lactose-free and low-allergen products
Lactose-free tablets can serve hospital formularies, institutional buyers, and markets with strong excipient-labeling preferences. A cellulose- or mannitol-based formula may also support a cleaner excipient profile. The opportunity is commercial rather than strongly patent-driven.
Orally disintegrating tablets
An orally disintegrating tablet could target patients with dysphagia, older adults, and settings where water is unavailable. Mannitol, crospovidone, flavoring, sweeteners, and taste-masking agents would require careful optimization because fosinopril and its degradation products may create taste and stability challenges.
An ODT product would likely require a new formulation and bioequivalence strategy. Its patent potential would be stronger than that of a conventional tablet if the formulation has a defined disintegration time, taste-masking system, stability advantage, or manufacturing process.
Oral liquid or suspension
A liquid formulation could address pediatric administration and swallowing difficulties. The commercial case is constrained by the regulatory status of pediatric use, chemical stability, preservative selection, dosing accuracy, and taste. FDA labeling states that safety and effectiveness in pediatric patients have not been established for fosinopril (FDA, 2017).
A ready-to-use solution would require stronger stability support than an extemporaneous suspension. A powder-for-reconstitution product could reduce shelf-life pressure but would add packaging and reconstitution controls.
Fixed-dose combination with hydrochlorothiazide
Fosinopril/hydrochlorothiazide is a logical lifecycle product for hypertension. Combination strengths can improve adherence and reduce prescription complexity. The commercial opportunity is limited by competition from other ACE inhibitor/thiazide products, including lisinopril/hydrochlorothiazide and enalapril/hydrochlorothiazide.
A combination product can justify separate development if it offers:
- Competitive pricing.
- Fewer tablets.
- Broad strength coverage.
- Reliable supply.
- Institutional formulary access.
- A differentiated excipient profile.
The combination is a small-molecule generic product, not a biosimilar, but it may require separate ANDA work and product-specific bioequivalence evidence.
How strong is the patent estate for fosinopril sodium?
The patent estate for the standard product is weak from an exclusivity perspective but manageable from a freedom-to-operate perspective. The absence of a strong active-ingredient patent does not eliminate risk in a new formulation program. Risk shifts to formulation, process, and combination patents.
| Development target |
Patent strength potential |
Regulatory complexity |
Commercial attractiveness |
| Standard 10/20/40 mg tablet |
Low |
Low |
Moderate |
| Lactose-free tablet |
Low to moderate |
Low |
Moderate |
| ODT |
Moderate |
Moderate |
Moderate |
| Oral liquid |
Moderate |
Moderate to high |
Niche |
| Fosinopril/HCTZ tablet |
Moderate |
Moderate |
Moderate |
| Sustained-release product |
Moderate to high |
High |
Uncertain |
| Novel salt or polymorph |
Potentially high |
High |
Low unless performance improves |
A new patent program should focus on measurable technical advantages. Examples include improved impurity control, reduced moisture-driven degradation, enhanced dissolution after storage, improved blend uniformity, or a manufacturing process that materially reduces batch failure.
What manufacturing and supply-chain barriers affect entry?
The active ingredient is available through established pharmaceutical supply channels, but the commercial risks include:
- API qualification and dual sourcing.
- Control of fosinopril-related impurities and degradation products.
- Moisture and temperature management.
- Lubricant variability.
- Tablet hardness and dissolution drift.
- Film-coating color consistency.
- Packaging that protects against humidity.
- Country-specific excipient compliance.
- Nitrosamine and elemental-impurity assessments where applicable.
A dual-source excipient strategy is practical for lactose, microcrystalline cellulose, povidone, crospovidone, and lubricant systems. The manufacturer should qualify alternate grades rather than assuming compendial equivalence guarantees equivalent tablet performance.
Which companies are challenging the fosinopril sodium market?
Competition comes primarily from generic manufacturers and contract suppliers. The market includes U.S. ANDA holders and international producers that supply fosinopril sodium tablets or combination products. Competitive differentiation is based on price, supply reliability, formulary contracts, strength availability, packaging, and regulatory reach.
The relevant competitive set also includes other ACE inhibitors:
| Drug |
Competitive advantage |
| Lisinopril |
Broad generic supply and strong prescriber familiarity |
| Enalapril |
Established generic and combination-product presence |
| Ramipril |
Strong cardiovascular positioning in several markets |
| Benazepril |
Generic hypertension and combination competition |
| Fosinopril |
Distinctive renal-excretion profile and established use in heart failure |
Fosinopril has a pharmacokinetic distinction because the active drug is eliminated through both hepatic and renal routes. The FDA label identifies this dual pathway as relevant to dosing considerations in renal impairment (FDA, 2017). That distinction supports clinical positioning but does not create meaningful generic exclusivity.
What revenue exposure and launch scenarios exist?
Public FDA and label sources do not establish a reliable current market-revenue figure for fosinopril sodium. The product is best viewed as a mature, price-sensitive generic with limited brand premium.
Three launch scenarios are commercially realistic:
- A standard ANDA tablet launch focused on low manufacturing cost and supply reliability.
- A differentiated combination or excipient-positioned product targeting institutional and specialty retail channels.
- A lifecycle product, such as an ODT or liquid, aimed at adherence and administration barriers.
The first scenario has the lowest regulatory risk but also the strongest price competition. The third has more defensible commercial positioning but requires clinical, stability, taste, packaging, and regulatory investment.
Key Takeaways
- Fosinopril sodium is an old, multisource ACE inhibitor with no meaningful current U.S. exclusivity.
- Standard 10 mg, 20 mg, and 40 mg tablets are primarily a cost, quality, and supply-chain opportunity.
- Common excipient systems include lactose, microcrystalline cellulose, crospovidone or croscarmellose sodium, povidone, silicon dioxide, and tablet lubricants.
- Excipient substitution alone is unlikely to support durable patent protection.
- Stronger formulation opportunities include ODTs, oral liquids, moisture-stable tablets, and fosinopril/hydrochlorothiazide combinations.
- Fosinopril sodium is not eligible for biosimilar treatment because it is a small molecule.
- Paragraph IV litigation is not the principal risk for the conventional tablet; new formulation patents would create the more relevant legal exposure.
- Commercial success depends on ANDA execution, reliable API and excipient sourcing, dissolution control, and competitive pricing.
FAQs
Is fosinopril sodium still commercially available?
Yes. Fosinopril sodium remains available as a generic oral tablet in multiple strengths, although product availability varies by country, manufacturer, and wholesaler.
Does fosinopril sodium require cold-chain distribution?
No. The product is an oral solid dosage form and does not generally require cold-chain distribution. Packaging and stability controls must still address moisture, temperature, and product-specific degradation.
Can fosinopril sodium be reformulated as a pediatric product?
A pediatric formulation can be developed, but FDA labeling states that pediatric safety and effectiveness have not been established. A liquid or suspension would require appropriate regulatory, stability, dosing, and palatability support.
Are fosinopril sodium excipients patentable?
An excipient combination can be patentable when tied to a novel, nonobvious technical result. Conventional substitution of lactose, cellulose, or a superdisintegrant generally offers limited patent strength without unexpected performance.
Is fosinopril sodium a good candidate for a fixed-dose combination?
Yes, particularly with hydrochlorothiazide. The opportunity is commercially viable but faces competition from established ACE inhibitor/thiazide combinations and requires separate product-development and regulatory work.
References
DailyMed. (n.d.-a). Fosinopril sodium tablet: Label information. U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/
DailyMed. (n.d.-b). Fosinopril sodium tablet, film coated: Label information. U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/
U.S. Food and Drug Administration. (2017). Fosinopril sodium tablets prescribing information. FDA.
U.S. Food and Drug Administration. (n.d.-a). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/
U.S. Food and Drug Administration. (n.d.-b). Drugs@FDA: FDA-approved drugs. https://www.accessdata.fda.gov/scripts/cder/daf/
